Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy. - Wikidata - wikimedia - TriplyDB

Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.

Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.

http://www.wikidata.org/entity/Q30825339

about

Interventions for central serous chorioretinopathy: a network meta-analysis Interventions for central serous chorioretinopathy: a network meta-analysis Indocyanine green-mediated photothrombosis as a new technique of treatment for persistent central serous chorioretinopathy.One-year results of reduced fluence photodynamic therapy for central serous chorioretinopathy: the outer nuclear layer thickness is associated with visual prognosis.Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study Topical nepafenac in treatment of acute central serous chorioretinopathy.Half-dose verteporfin combined with half-fluence photodynamic therapy for chronic central serous chorioretinopathy.The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy.Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.Polypoidal choroidal vasculopathy and history of central serous chorioretinopathy.Transpupillary thermotherapy for atypical central serous chorioretinopathy.High-dose antioxidants for central serous chorioretinopathy; the randomized placebo-controlled study.The effect of photodynamic therapy on macular sensitivity in eyes with acute central serous chorioretinopathy.Helicobacter pylori infection and eye diseases: a systematic review.Central serous chorioretinopathy: update on pathophysiology and treatment.Factors influencing the visual acuity of chronic central serous chorioretinopathy Morphologic Changes in the Foveal Photoreceptor Layer before and after Laser Treatment in Acute and Chronic Central Serous Chorioretinopathy Documented in Spectral-Domain Optical Coherence Tomography.Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome Oral Rifampin treatment for longstanding chronic central serous chorioretinopathy.The association between choroidal thickness variations and response to intravitreal bevacizumab in central serous chorioretinopathy.Comparing half-dose photodynamic therapy with high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy (the PLACE trial): study protocol for a randomized controlled trial.Intravitreal bevacizumab for choroidal neovascularization secondary to non-age-related macular degeneration Variation in Visual Outcome to Anti-Vascular Endothelial Growth Factors in Choroidal Neovascular Membrane Developing in Eyes with Previously Untreated Versus Focal Laser-Treated Central Serous Chorioretinopathy.Changes in Choroidal Structures in Eyes with Chronic Central Serous Chorioretinopathy after Half-Dose Photodynamic Therapy Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).Association of Choroidal Neovascularization and Central Serous Chorioretinopathy With Optical Coherence Tomography Angiography.Factors affecting the visual outcome in acute central serous chorioretinopathy.Central serous chorioretinopathy: a review of epidemiology and pathophysiology.Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy.Comparison of efficacy between low-fluence and half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.The Ocular Manifestations of Drugs Used to Treat Multiple Sclerosis.Circadian disturbance and idiopathic central serous chorioretinopathy.Intravitreal Bevacizumab for Treatment of Central Serous Chorioretinopathy.Changes in macular sensitivity after half-dose photodynamic therapy for chronic central serous chorioretinopathy.Changes of outer retinal microstructures after photodynamic therapy for chronic central serous chorioretinopathy.Microsecond yellow laser for subfoveal leaks in central serous chorioretinopathy.Role of Avastin in management of central serous chorioretinopathy.Low-dose aspirin as treatment for central serous chorioretinopathy Short-term efficacy of intravitreal dobesilate in central serous chorioretinopathy.

P2860

Q24186996-A96137CA-913D-4701-A533-C4305F67DB2E Q24188115-41AF1A89-F3C2-4213-A37A-6A6DEFCA19A6 Q30905661-8BDF5ABD-56E5-42D0-ABF4-F98256625FDF Q31112014-26556E78-AA04-4961-8AA7-40300ADAD9CF Q33195722-3E8638BF-BAD9-4214-A323-97D0EF08E27B Q33239033-15D71BA8-0DF2-42E5-9081-88757E6CBA4F Q33597082-702A8103-F634-4374-B1AE-6DB02FC91CBE Q33705962-ADB97A27-CD1A-4279-99E3-594D1AF931BF Q33899231-C86EAA45-D308-4725-8F06-1081E364D8CD Q33996055-8E34A237-5B32-463C-9218-45C790BD81DD Q34055052-34233EDE-5905-4EF8-9A3B-8D4AE358C7B3 Q34158234-8B8E742E-E04C-43A0-AD5F-1315D78EB69D Q34338611-25EAF2C3-04F3-43DA-98B4-A95128E05D88 Q34394791-B1FB93B6-A8D2-49DC-B495-08C5751DEAB0 Q34454857-B1DFF37F-8390-466D-8515-915D396AD342 Q34587658-32EA1723-0F5E-4541-BD3E-E1034C1BF6E6 Q34695063-82781811-13D9-4634-AEAF-2A74C37FAE61 Q35028601-E7594A49-6F2E-487E-B243-E11000CB2AC3 Q35088788-3B031E7C-53C8-4759-80AD-BEB19AB0C1B5 Q35582953-8C7C1FDF-697B-4A0C-86B9-BEE41C3CBCA2 Q35657257-A9CDD200-EC36-42F8-8876-F1C7017C6C9D Q35782233-2A841171-6443-416C-9AD9-B43B7B63423B Q36050969-2A2F5CA6-193A-483E-8E22-8C592ABD6C1A Q36106039-4FC2335C-D669-4ACA-80C4-B021A518D7FD Q36135515-9F478261-5693-4CEC-B70C-8D06346AD0AD Q36407625-43BFAB30-8120-4C5E-BB04-DD70D0745C55 Q36487164-88C29F3B-78EE-47CE-8E1C-4837D3EF5A99 Q37723609-121DF24E-DAA5-4C47-9047-D852BC793E4D Q38025702-8A71830A-C317-4ED1-B56D-44182CAD4F8C Q38644045-07782603-B26A-485D-881C-0CF07B566DDA Q38701151-5942DD35-3297-471E-9906-BB3268B8AB1C Q39127843-5C185F73-D926-4734-AADA-86D2DE6D1312 Q40516288-53A826C3-8850-4AE9-9C97-8A5184F7FD68 Q41190093-41B5EECD-6C6F-4722-A273-4084575644DC Q41362947-7482163E-8CA5-409E-AB2A-CD33B463D591 Q41484477-CF6141C2-F61C-4E97-ACCD-12F14B60CE30 Q41746219-55AF6B06-6B84-4C45-A542-CE424DC257F0 Q41774757-59D8A198-8A21-406F-AD3E-0CD37F683F7C Q41899388-05E8622E-7529-4808-87B7-57CEED6C2173 Q42153332-7FC16062-0609-4CED-A18D-BA0095DA6503

P2860

Factors associated with reduced visual acuity during long-term follow-up of patients with idiopathic central serous chorioretinopathy.

http://www.wikidata.org/entity/Q30825339

description

2002 nî lūn-bûn

@nan

2002 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Factors associated with reduce ...... tral serous chorioretinopathy.

@ast

Factors associated with reduce ...... tral serous chorioretinopathy.

@en

type

label

Factors associated with reduce ...... tral serous chorioretinopathy.

@ast

Factors associated with reduce ...... tral serous chorioretinopathy.

@en

prefLabel

Factors associated with reduce ...... tral serous chorioretinopathy.

@ast

Factors associated with reduce ...... tral serous chorioretinopathy.

@en

P1433

Q30825339-D147E880-E53A-4E03-BC58-CF9CEE411829

P1476

Q30825339-8C94EFDD-292B-4DFD-9BEB-35D0F43A6923

P2093

Q30825339-0D5090D8-6736-41ED-9F2A-213F3B391C7D

Q30825339-3929C18C-98BF-4FF7-B74A-A6C815CBD38E

Q30825339-563DF86A-F5B7-4A95-AC82-8B4457B7BDDE

Q30825339-63D1E2C7-C30D-4F2D-810F-A7D1DCDD2DA2

Q30825339-6C2BA4E1-3F52-4B8E-A508-F73C50F53C3A

Q30825339-76BE8C60-DBEC-412A-A02F-ACF33E75466F

Q30825339-96CC5B89-1A33-490D-9123-55D1BAB26AE7

Q30825339-CD33F0F3-F874-484C-AE3F-CD7649DF9004

P304

Q30825339-A0A575B4-066B-4388-B6CC-F1EF06853C2F

P31

Q30825339-F9485DB5-6174-4E7C-8666-E629737FAE19

P356

Q30825339-0920DD27-EFAD-4541-9432-42A18FA6417A

P433

Q30825339-BCEAE8F5-9C31-4D1F-9352-B52EFB9B8B65

P478

Q30825339-DC444C55-03D9-4C9E-A07C-04E6758A2A41

P577

Q30825339-876BB6E3-057A-4F20-BCDC-2B4A58F7E2CC

P5875

Q30825339-35295039-48D6-4E04-8DEF-6285804078A3

P698

Q30825339-DB98A90F-7B81-4079-BC1E-EC7A77EEA34E

P921

Q30825339-73518A65-0A3E-4827-80CB-51AFC39A2728

P356

00006982-200202000-00004

P1433

P1476

Factors associated with reduce ...... tral serous chorioretinopathy.

@en

P2093

Harry W Flynn

http://www.w3.org/2001/XMLSchema#string

Ingrid U Scott

http://www.w3.org/2001/XMLSchema#string

J Donald M Gass

http://www.w3.org/2001/XMLSchema#string

Mary Lou Lewis

http://www.w3.org/2001/XMLSchema#string

Phillip J Rosenfeld

http://www.w3.org/2001/XMLSchema#string

Roy H Loo

http://www.w3.org/2001/XMLSchema#string

Timothy G Murray

http://www.w3.org/2001/XMLSchema#string

William E Smiddy

http://www.w3.org/2001/XMLSchema#string

P304

19-24

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/00006982-200202000-00004

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2002-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11478015

http://www.w3.org/2001/XMLSchema#string

P698

11884873

http://www.w3.org/2001/XMLSchema#string

P921